STAGE IV UVEAL MELANOMA AJCC V7
Clinical trials for STAGE IV UVEAL MELANOMA AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV UVEAL MELANOMA AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IV UVEAL MELANOMA AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for rare eye cancer
Disease control OngoingThis study tests two drugs, trametinib and GSK2141795, in people with advanced uveal melanoma that has spread. The goal is to see if the combination works better than trametinib alone at slowing cancer growth. About 42 adults with this rare eye cancer will take part.
Matched conditions: STAGE IV UVEAL MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New hope for rare eye cancer: drug targets spreading tumors
Disease control OngoingThis study tests a drug called vorinostat in 40 people with uveal melanoma that has spread to other parts of the body. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see if the drug can shrink tumors and help control the disease.
Matched conditions: STAGE IV UVEAL MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC